Source: Eur Respir J, 59 (2) 2004587; 10.1183/13993003.04587-2020



Rating:

Share or cite this content

Citations should be made in the following way:
Toby M. Maher, Kevin K. Brown, Michael Kreuter, Anand Devaraj, Simon L.F. Walsh, Lisa H. Lancaster, Elizabeth A. Belloli, Maria Padilla, Juergen Behr, Rainer-Georg Goeldner, Kay Tetzlaff, Rozsa Schlenker-Herceg, Kevin R. Flaherty. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. Eur Respir J, 59 (2) 2004587; 10.1183/13993003.04587-2020

Member's Comments

No comment yet.

Related content which might interest you: Effect of pirfenidone on IPF progression Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Effect of baseline composite physiologic index on benefit of nintedanib in IPF Source: International Congress 2016 – IPF treatment I Year: 2016 Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Clinical use of interstitial lung disease guidelines Source: Eur Respir Mon; 2009: 46: 386–395 Year: 2009 Predictors of progression in systemic sclerosis patients with interstitial lung disease Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019 Year: 2020 Clinical characteristics of patients with unclassifiable interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015 Clinical trials in interstitial lung disease Source: Eur Respir Mon; 2009: 46: 67–84 Year: 2009 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Different definitions of pulmonary hypertension in interstitial lung disease: a prognostic evaluation. Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage Source: ERJ Open Res, 5 (2) 00127-2018; 10.1183/23120541.00127-2018 Year: 2019 Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Effects of pulmonary rehabilitation in patients with interstitial lung disease (ILD) Source: Annual Congress 2009 - New treatment and outcome measures for pulmonary rehabilitation Year: 2009 Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015